Literature DB >> 19758181

Hyperactivity induced by antiphospholipid syndrome serum.

Assaf Menachem1, Joab Chapman, Aviva Katzav.   

Abstract

Antiphospholipid syndrome (APS) is a multisystem disorder characterized by arterial and venous thrombosis, pregnancy morbidity, and neuropsychiatric manifestations. Antiphospholipid IgG injected intracerebroventricularly (i.c.v.) cause behavioral hyperactivity in mice. In the present study we investigated the effects of APS whole-serum i.c.v. administration in female Balb/C mice. Control mice were injected with serum derived from healthy subjects or saline solution. Behavior was assessed by the staircase apparatus which combines locomotor (stair-climbing) exploratory activities and rearing as a measure of anxiety. Mice injected with serum from APS patients or serum from normal subjects showed a trend to an increase in the number of stairs climbed in the APS group. The results suggest a differential effect of specific IgG and other serum components in the CNS manifestations of APS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758181     DOI: 10.1111/j.1749-6632.2009.04876.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Increased anti-phospholipid antibodies in autism spectrum disorders.

Authors:  Milo Careaga; Robin L Hansen; Irva Hertz-Piccotto; Judy Van de Water; Paul Ashwood
Journal:  Mediators Inflamm       Date:  2013-09-23       Impact factor: 4.711

3.  16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus.

Authors:  Shaye Kivity; Aviva Katzav; Maria Teresa Arango; Moran Landau-Rabi; Yaron Zafrir; Nancy Agmon-Levin; Miri Blank; Juan-Manuel Anaya; Edna Mozes; Joab Chapman; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.